Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility
International Journal of Molecular Sciences · 04.08.2026 · 27 (15) · 6988
DOI: 10.3390/ijms27156988 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.08.2026. Verfasst von Mihai Olteanu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine-Pneumology, Faculty of Medicine, University of Medicine and Pharmacy from Craiova, 200349 Craiova, Romania. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy of Craiova.
Abstract (Originalsprache)
Lung cancer remains the leading cause of cancer-related mortality worldwide, and durable benefit from immune checkpoint inhibitors is limited by immune exclusion, microenvironmental immunosuppression, and toxicity. This narrative translational review evaluates whether endobronchial intratumoral delivery of immuno- and gene-based therapies can transform bronchoscopic access into a therapeutic platform linking local tumour intervention with systemic antitumour immunity. We synthesise evidence on endobronchial ultrasound, electromagnetic navigation bronchoscopy, and robotic-assisted bronchoscopy, together with local checkpoint blockade, cytokine and mRNA-lipid nanoparticle constructs, oncolytic virotherapy, dendritic-cell approaches, viral and non-viral gene transfer, and enzyme- or metabolite-based strategies. Current clinical evidence remains preliminary, consisting mainly of Phase I trials, small prospective cohorts, and case-based signals, with feasibility and safety observations but no completed randomised trial demonstrating efficacy against standard-of-care systemic therapy. The most plausible candidates are patients with advanced or recurrent NSCLC, bronchoscopically accessible lesions, inadequate response to systemic immunotherapy, and immune-excluded or locally immunosuppressed tumours. Biomarkers such as PD-L1, tumour mutational burden, CD8+ infiltration, tertiary lymphoid structures, radiomics, and circulating tumour DNA require validation. This review integrates delivery technology, immune mechanisms, statistical evidence appraisal, biomarker limitations, AI-guided planning, and global feasibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine-Pneumology, Faculty of Medicine, University of Medicine and Pharmacy from Craiova, 200349 Craiova, Romania.
- Department of Medical Informatics and Biostatistics, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
ORCID-Profile: Mihai Olteanu, Ramona Cioboată, Virginia Maria Rădulescu
Förderung
- University of Medicine and Pharmacy of Craiova
Zitieren
APA
Olteanu, M., Andrei, G. M., Cioboată, R., & Rădulescu, V. M. (2026). Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility. International Journal of Molecular Sciences, 27(15), 6988. https://doi.org/10.3390/ijms27156988
Vancouver
Olteanu M, Andrei GM, Cioboată R, Rădulescu VM. Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility. International Journal of Molecular Sciences. 2026;27(15):6988. doi:10.3390/ijms27156988
BibTeX
@article{Olteanu2026,
author = {Olteanu, Mihai and Andrei, Gabriela Marina and Cioboată, Ramona and Rădulescu, Virginia Maria},
title = {Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6988},
doi = {10.3390/ijms27156988}
}
EUVIMED